Triple threat: new combo aims to boost immunotherapy in tough breast cancer

NCT ID NCT07015853

Not yet recruiting Disease control Sponsor: Stephen Shiao Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding a targeted drug (axatilimab) and radiation to the immunotherapy pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer who have already tried immunotherapy. About 34 participants will receive all three treatments. The main goal is to see how many patients have their tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab, radiotherapy, and axatilimab
What this could lead to: If successful, this combination could improve tumor shrinkage and control in metastatic triple-negative breast cancer that has not responded to prior immunotherapy.
What could go wrong: This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.